PEG-liposomal doxorubicin as a potential agent for canine metastatic osteosarcoma – in vitro and ex ovo studies
2023
Walewska Magdalena | Małek Anna | Taciak Bartosz | Wojtalewicz Anna | Wilk Sylwia | Wojtkowska Agata | Zabielska-Koczywąs Katarzyna | Lechowski Roman
Appendicular osteosarcoma (OSA) is a highly aggressive and metastatic primary bone tumour in dogs. Standard therapy is amputation and adjuvant chemotherapy (e.g. with doxorubicin). Liposomal drug delivery may augment therapeutic efficacy and reduce negative side effects. Polyethylene glycol (PEG)-liposomal doxorubicin treats human metastatic cancers effectively. The study aimed was to evaluate PEG-liposomal doxorubicin’s inhibitory effect on canine metastatic proliferation and migration in vitro. It also aimed to appraise the drug’s extravasation inhibition in vivo using the human medicine–proven chick embryo chorioallantoic membrane ex ovo model.
Show more [+] Less [-]AGROVOC Keywords
Bibliographic information
This bibliographic record has been provided by Directory of Open Access Journals
